High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2

I-Ping Yang\(^1,2,\ast\), Hsiang-Lin Tsai\(^3,4,5,6,\ast\), Ching-Wen Huang\(^5,6\), Chien-Yu Lu\(^7,8\), Zhi-Feng Miao\(^6\), Se-Fen Chang\(^9\), Suh-Hang Hank Juo\(^1,4,10,11,12,13\), Jaw-Yuan Wang\(^1,4,5,6,11,12,13\)

\(^1\) Department of Genomic Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^2\) Department of Nursing, Shu-Zen College of Medicine and Management, Kaohsiung, Taiwan
\(^3\) Department of Surgery, Division of General Surgery Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
\(^4\) Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^5\) Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^6\) Department of Surgery, Division of Gastroenterology and General Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^7\) Department of Internal Medicine, Division of Gastroenterology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^8\) Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^9\) Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^10\) Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
\(^11\) Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^12\) Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
\(^13\) Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan

\* These authors have contributed equally to this work

Correspondence to: Jaw-Yuan Wang, e-mail: cy614112@ms14.hinet.net, jayuwa@cc.kmu.edu.tw

Keywords: hyperglycemia, colorectal cancer, miR-16, DM, prognosis

Received: August 29, 2015  Acccepted: January 19, 2016  Published: February 25, 2016

ABSTRACT

The high prevalence of type 2 diabetes mellitus in colorectal cancer patients is a crucial public health issue worldwide. The deregulation of microRNAs has been shown to be associated with the progression of CRC; however, the effects of high blood sugar levels on miR deregulation and, in turn, CRC remain unexplored. In this study, 520 CRC patients were classified into two groups according to their blood sugar levels (≥110 or <110 mg/dL). Clinicopathologic features, clinical outcomes, and serum miR-16 levels of the two groups were then analyzed, while cell cycles, cell proliferation, migration, and cellular miR-16 expression were investigated via D-(+)-glucose administration. Additionally, the target genes of miR-16 were identified. Through multivariate analysis, both the disease-free survival and overall survival of the CRC patients were found to be associated with the UICC stage, perineural invasion, and blood glucose levels (P < 0.05). Serum miR-16 levels were significantly lower in the high blood glucose patients than in the normal blood glucose patients (P = 0.0329). With D-(+)-glucose administration, the proliferation and migration of CRC cells in vitro increased remarkably (P < 0.05), while their accumulation in the G1 phase decreased significantly. Cellular miR-16 expression was suppressed by D-(+)-glucose administration. The expression levels of two target genes, Myb and VEGFR2, were affected significantly by miR-16, while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration. Hyperglycemia can impact the clinical outcomes of CRC patients, likely by inhibiting miR-16 expression and the expression of its downstream genes Myb and VEGFR2.
INTRODUCTION

Colorectal cancer (CRC) is a significant public health problem. Nearly one million new cases of CRC are diagnosed annually worldwide, and approximately half a million of these cases result in death [1]. Although radical surgical resection can be highly effective for localized diseases, 25-40% of patients develop recurrence/metastasis after surgery [2]. The recurrence of CRC is a time-limited phenomenon, and it has been shown that the length of patients’ recurrence periods correlates strongly with the length of their survival periods [3, 4]. Presently, no ideal biomarker or indicator for predicting the recurrence/metastasis of CRC after operation exists [5, 6]. Continuous efforts have been made to enhance the methods of early tumor detection so as to assist physicians in intensifying surveillance and therapeutic strategies, thereby improving the patients’ prognoses [5, 7, 8].

The proper control of metabolic homeostasis is crucial to maintaining human physiology and health. Relatedly, systematic review reports have demonstrated that fatty-acid metabolism plays a significant role in the tumorigenesis of human CRC [9]. Moreover, increased glycolytic activity among malignant tumor cells has been demonstrated both in vivo and in vitro [10], while diabetic people have been shown to have an increased risk of CRC as compared to non-diabetics [11]. Mature microRNAs (miRs) that function as translational repressors have recently been found to be key regulators of metabolism and tumorgenesis [12–17]. Tumor-derived microvesicles are enriched with bioactive molecules, and plasma miRs. Microvesicles miRs are protected from endogenous RNase activity and are involved in cancer progression and immune-response inhibition [18]. Circulating miRs have been shown to be promising circulating biomarkers for CRC detection and progression [19–22]. Although several studies have focused on the deregulation of miRs, involving either the pathogenesis of metabolic disorders [12, 13] or CRC carcinogenesis [14–17], studies in the deregulation of miRs involving glucose metabolism and CRC recurrence/prognosis are sparse. Previous studies have shown the downregulation of the serum miR-16 family in patients with metabolic syndrome [23, 24] and the downregulation of miR-195 in patients with poor prognoses in CRC [25]. Consequently, this study explores the correlation between the glycolysis-related miRs/relevant miRs target genes and CRC relapse/prognosis.

In the current study, we attempted to determine the correlations, if any, between the serum blood sugar levels and clinical outcomes of CRC patients. Furthermore, we investigated in vitro whether high serum blood sugar levels could affect the prognoses of CRC patients through miRs deregulation and the modulation of miRs downstream genes.

RESULTS

Demographic data and clinical outcomes

The clinicopathologic features of 520 independent CRC patients (312 in the normal glucose group vs. 208 in the high glucose group) are summarized in Table 1. The median blood sugar level of the patients was 105 mg/dL, with a range from 70 to 395. The median age of the patients was 66 years, with a range from 24 to 89. Patients in the DM history group had significantly higher blood sugar levels than those in the non-diabetes group (P < 0.0001, Table 1). In addition, the results in Table 1 also indicate significant differences in tumor size (P = 0.042), age (P = 0.005), and the presence of perineural invasion (P = 0.022) between the normal blood sugar group (<110 mg/dL) and the high blood sugar group (≥110 mg/dL), but no significant differences in terms of other clinicopathologic features, including gender (P = 0.942), tumor location (P = 0.874), tumor invasion depth (P = 0.282), lymph node metastasis (P = 0.288), stage (P = 0.413), vascular invasion (P = 0.102) and differentiation grade (P = 0.964).

Further stratification of CRC patients according to DM history status (Table 2) showed that patients in the normal blood glucose level group with or without a DM history had a lower percentage of relapse compared to patients in the high blood glucose level group (P = 0.0001 and 0.0115, respectively). Patients without a history of DM and who maintained a blood glucose level below 110 mg/dL had a better overall survival rate than those with a high blood glucose level (P = 0.0004, Table 2), but no significant differences between high and normal blood glucose groups among patients with DM were observed (P = 0.5225, Table 2).

Impact on disease-free survival (DFS) and overall survival (OS)

Using Cox regression hazard analysis, the prognostic factors for DFS and OS for CRC patients was shown (Table 3). Multivariate analyses showed the advanced UICC stage (P < 0.0001, HR: 2.200, 95% CI: 1.618-3.005, Table 3), the presence of perineural invasion (P = 0.0003, HR: 1.773, 95% CI: 1.299-2.414, Table 3), DM history (P = 0.025, HR: 0.660, 95% CI: 0.453-0.950, Table 3), and high blood sugar levels (P < 0.0001, HR: 2.206, 95% CI: 1.467-2.788, Table 3) to be significant independent poor prognostic factors for DFS. For OS, the advanced UICC stage (P < 0.0001, HR: 2.294, 95% CI: 1.536-3.462, Table 3), tumor size ≥5 cm (P = 0.050, HR: 1.467, 95% CI: 1.000-2.156, Table 3), presence of perineural invasion (P = 0.016, HR: 1.656, 95% CI: 1.101-2.480, Table 3), and high blood sugar levels (P = 0.002, HR: 1.917, 95% CI: 1.265-2.896, Table 3) to be significant independent poor prognostic factors. DM status was a significant
independent prognostic factor for DSF, however, high blood glucose level was a significant independent prognostic factor for both DSF and OS. Blood sugar level was considered to be more significant than DM status for the clinical outcome of CRC patients.

Table 1: Baseline characteristics of 520 colorectal cancer patients based on serum blood sugar concentrations using univariate analysis

| Variables                          | Serum blood sugar<110 mg/dL (n = 312) | Serum blood sugar≥110 mg/dL (n = 208) | P value |
|------------------------------------|--------------------------------------|--------------------------------------|---------|
| Age (y) (Mean ± SD)                | 63.32 ± 12.49                        | 66.42 ± 12.30                        | 0.005   |
| DM<sup>2</sup> no                  | 278 (89.10)                          | 107 (51.44)                          | <0.0001 |
| DM<sup>2</sup> yes                 | 34 (10.90)                           | 101 (48.56)                          |         |
| Gender female                      | 130 (41.67)                          | 86 (41.35)                           |         |
| Gender male                        | 182 (58.33)                          | 122 (58.65)                          | 0.942   |
| Tumor size <5 cm                   | 196 (62.82)                          | 112 (53.85)                          | 0.042   |
| Tumor size ≥5 cm                   | 116 (37.18)                          | 96 (46.15)                           |         |
| Location colon                     | 223 (71.47)                          | 150 (72.12)                          | 0.874   |
| Location rectum                    | 89 (28.53)                           | 58 (27.88)                           |         |
| Invasion depth T1                  | 19 (6.09)                            | 13 (6.25)                            | 0.282   |
| Invasion depth T2                  | 51 (16.35)                           | 24 (11.54)                           |         |
| Invasion depth T3                  | 227 (72.76)                          | 155 (74.52)                          |         |
| Invasion depth T4                  | 15 (4.81)                            | 16 (7.69)                            |         |
| Lymph node metastasis No           | 188 (60.26)                          | 115 (55.56)                          | 0.288   |
| Lymph node metastasis Yes          | 124 (39.74)                          | 92 (44.44)                           |         |
| Stage II                           | 133 (42.63)                          | 89 (42.79)                           | 0.413   |
| Stage III                          | 126 (40.38)                          | 92 (44.23)                           |         |
| Vascular invasion No               | 246 (78.85)                          | 151 (72.60)                          | 0.102   |
| Vascular invasion Yes              | 66 (21.15)                           | 57 (27.40)                           |         |
| Perineural invasion Yes            | 83 (26.60)                           | 75 (36.06)                           | 0.022   |
| Perineural invasion No             | 229 (73.40)                          | 133 (63.94)                          |         |
| Grade MD                           | 267 (85.58)                          | 177 (85.10)                          | 0.964   |
| Grade PD                           | 33 (10.58)                           | 22 (10.58)                           |         |
| Grade A                            | 301 (96.47)                          | 195 (93.75)                          |         |
| Type A                             | 9 (2.88)                             | 11 (5.29)                            | 0.352   |
| Type S                             | 2 (0.64)                             | 2 (0.96)                             |         |

<sup>1</sup>AC (Ante cibum= before eating) serum blood sugar before surgery

<sup>2</sup>Confirmed diagnosis of diabetes mellitus (DM) before surgery

<sup>3</sup>WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated

<sup>4</sup>A: Adenocarcinoma; M: Mucinous carcinoma; S: Signet-ring cell carcinoma.

### Effects of differing glucose concentrations on colon cancer cell proliferation

Three thresholds of D(+)-glucose concentrations (i.e., a baseline concentration of 5 mM (90 mg/dL)
Table 2: Correlation between postoperative relapse, survival and diabetes mellitus (DM) history in 520 UICC1 stage I-III colorectal cancer patients

| Variables          | Blood sugar <110 mg/dL (N = 278) No(%) | Blood sugar ≥110 mg/dL (N = 107) No(%) | P value | Blood sugar <110 mg/dL (N = 34) No(%) | Blood sugar ≥110 mg/dL (N = 101) No(%) | P value |
|--------------------|----------------------------------------|--------------------------------------|---------|--------------------------------------|--------------------------------------|---------|
| Relapse2           | No                                     | 192 (69.06)                          | 51 (47.66) |                                      |                                      | 0.0001  |
|                    | Yes                                    | 86 (30.94)                           | 56 (52.34) |                                      |                                      | 0.0115  |
| Overall Survival   | Yes                                    | 230 (82.73)                          | 70 (65.42) |                                      |                                      | 0.0004  |
|                    | No                                     | 48 (17.27)                           | 37 (34.58) |                                      |                                      | 0.5225  |

1UICC: Union for International Cancer Control
2Local recurrence or distant metastases after surgery

and the two higher concentrations of 10 mM (181 mg/dL) and 15 mM (271 mg/dL) were used to examine the role of glucose administration on the tumorigenesis of colon cancer cells. Caco2, SW480, and SW620 cells were treated for 24 h under the varying D-(+)-glucose concentrations (5, 10 and 15 mM). As shown in Figure 1A, the proliferation rate of Caco2 and SW620 by 10 mM of D-(+)-glucose administration increased significantly at 24 h (P = 0.0053 and 0.0035, respectively), compared to the rate by 5 mM of D-(+)-glucose administration. The proliferation rate of Caco2 and SW620 by 15 mM of D-(+)-glucose administration increased significantly at 24 h compared to the rate at 5 mM of D-(+)-glucose administration (both P < 0.0001). The proliferation rate of SW480 cells under various D-(+)-glucose concentrations did not vary significantly at 24 h (Figure 1A). Using flow cytometry, we further examined the influence of the various D-(+)-glucose concentrations on cell cycles. The rate of growth of SW480 cells was slower, and their accumulation in the G1 phase at 5 mM of D-(+)-glucose was higher than the accumulation rates for the other two cell lines (83.57% in SW480 (Supplementary Figure S1) vs. 55.15% in Caco2 or 51.15% in SW620 (Figure 1B)).

Effects of differing glucose concentrations on the colon cancer cell cycle

For Caco2 cells after 24 h of incubation, accumulation in the G1 phase at the higher glucose concentrations (55.15% in 5 mM of D-(+)-glucose vs. 49.22% in 10 mM of D-(+)-glucose and 49.78% in 15 mM of D-(+)-glucose; P = 0.0002 and 0.0014, respectively (Figure 1B)) while accumulation in the G2 phase was increased significantly at the higher concentrations (2.52% in 5 mM of D-(+)-glucose vs. 6.22% in 10 mM of D-(+)-glucose and 6.54% in 15 mM of D-(+)-glucose; P = 0.0186 and 0.0152, respectively (Figure 1B)). For SW620 cells after 24 h of incubation, a significantly decreased accumulation in the G1 phase at the higher concentrations (51.15% in 5 mM of D-(+)-glucose and 50.02% in 10 mM of D-(+)-glucose vs. 47.93% in 15 mM of D-(+)-glucose, P = 0.0315 and 0.089, respectively; Figure 1B) was found. A significantly increased accumulation in the S phase at the highest concentration (42.32% in 5 mM of D-(+)-glucose and 41.79% in 10 mM of D-(+)-glucose vs. 46.68% in 15 mM of D-(+)-glucose, P = 0.0129 and 0.0094, respectively (Figure 1B)) and a significantly decreased accumulation in the G2 phase at the highest concentration (6.53% in 5 mM of D-(+)-glucose vs. 8.20% in 10 mM of D-(+)-glucose and 5.54% in 15 mM of D-(+)-glucose, P = 0.223 and 0.032, respectively (Figure 1B)) were found. The two colon cancer cell lines (Caco2 and SW620) were shown to have significantly decreased accumulations in the G1 phase when subjected to the high D-(+)-glucose concentrations.

Due to the slow growth rate of SW480 cells, the incubation time for the SW480 cell cycle experiment was extended to 48 h. After 48 h of incubation (Supplementary Figure S1A), accumulation in the G1 phase decreased significantly in the higher concentrations (83.57% in 5 mM of D-(+)-glucose vs. 79.63% in 10 mM of D-(+)-glucose and 79.35% in 15 mM of D-(+)-glucose, P = 0.0079 and 0.0054, respectively), while the accumulation in the G2 phase increased significantly (1.52% in 5 mM of D-(+)-glucose vs. 4.19% in 10 mM of D-(+)-glucose and 4.36% in 15 mM of D-(+)-glucose, both P < 0.0001).

Effects of differing glucose concentrations on cell migration ability

For the Caco2 cells, wound healing analysis indicated that the gap distances for 5mM, 10mM, and 15mM glucose concentrations at 0 h were 1.84 mm, 1.84 mm, and 1.88 mm, respectively. After 24 h of incubation, the narrowest gap distances decreased to 1.64 mm in 5 mM of D-(+)-glucose, 0.76 mm in 10 mM of D-(+)-glucose, and 0.72 mm in 15 mM of D-(+)-glucose (both
P > 0.05). After 48 h, the gap distances narrowed down to 0.48 mm in 5 mM of D-(+)-glucose vs. 0.08 mm in 10 mM of D-(+)-glucose and 0 mm in 15 mM of D-(+)-glucose (P = 0.017 and 0.002, respectively) (Figure 1C). For the SW480 and SW620 cells, cell migration was also examined in terms of the varying concentrations of D-(+)-glucose. The SW480 cells were shown to react in one particular way by floating into the media rather than attaching to a new area of the plate (Supplementary Figure S2A), while the SW620 cells were shown to react in another way by piling on top of each other and forming a large lump (Supplementary Figure S2B). These results show that while the colon cancer cells clearly exhibited increased migration ability when subjected to high concentrations of glucose, the SW480 and SW620 cell lines were not suitable for use in wound healing analysis.

**Decreased circulating miR-16 expression in high blood sugar group**

Preoperative serum miR-16 levels varied significantly between the low glucose (<110 mg/dL, N=46) and high glucose (≥110 mg/dL, N=44) patients. The mean of $\log_{10}(2^{-\Delta Ct})$ was -0.68 in the normal glucose group and -1.22 in the high glucose group (Figure 2A). Therefore, serum miR-16 levels decreased 3.5-fold in high glucose patients compared to those in the normal glucose group (P = 0.0329).

| Variables                           | Number | DFS Univariate analysis | DFS Multivariate analysis | OS Univariate analysis | OS Multivariate analysis |
|-------------------------------------|--------|-------------------------|---------------------------|------------------------|--------------------------|
|                                     |        | P value | HR (95% CI)       | P value | HR (95% CI)       | P value | HR (95% CI)       | P value | HR (95% CI)       |
| Sex (Male/ Female)                  | 304/216| 0.651   | 1.069 (0.801-1.434) | 0.884   | 1.022 (0.762-1.379) | 0.258   | 1.242 (0.854-1.827) | 0.391   | 1.184 (0.807-1.756) |
| Age (≥65/ <65) years                | 281/239| 0.149   | 0.810 (0.608-1.078) | 0.497   | 0.902 (0.670-1.214) | 0.687   | 0.927 (0.642-1.341) | 0.705   | 1.077 (0.734-1.583) |
| Invasive depth (T4 + T3/ T2 + T1)  | 413/107| <0.0001 | 1.239 (1.539-3.766) | 0.103   | 1.461 (0.929-2.403) | 0.005   | 2.994 (1.239-3.830) | 0.602   | 1.170 (0.663-2.209) |
| Stage (III/II+ I)                  | 218/302| <0.0001 | 2.200 (1.923-3.448) | <0.0001 | 2.719 (1.869-4.003) | <0.0001 | 1.827 (1.536-3.642) |
| Tumor size (≥5/ <5)cm              | 212/308| 0.061   | 2.218 (1.661-2.953) | 0.0001  | 1.773 (1.299-2.414) | 0.0001  | 2.074 (1.430-2.996) | 0.016   | 1.656 (1.101-2.480) |
| Vascular invasion (yes/ no)        | 123/397| <0.0001 | 2.171 (1.378-2.531) | 0.492   | 1.123 (0.805-1.555) | <0.0001 | 2.370 (1.617-3.438) | 0.076   | 1.460 (0.961-2.203) |
| Perineural invasion (yes/ no)      | 158/362| <0.0001 | 2.184 (1.661-2.953) | 0.0003  | 1.773 (1.299-2.414) | 0.0001  | 2.074 (1.430-2.996) | 0.016   | 1.656 (1.101-2.480) |
| Blood sugar (≥110/ <110 mg/dL)     | 208/312| <0.0001 | 1.782 (1.339-2.373) | <0.0001 | 2.026 (1.467-2.788) | <0.0001 | 2.185 (1.236-2.585) | 0.002   | 1.917 (1.265-2.896) |
| DM history (yes/ no)               | 135/385| 0.843   | 0.967 (0.689-1.334) | 0.025   | 0.660 (0.453-0.950) | 0.972   | 0.993 (0.641-1.493) | 0.103   | 0.679 (0.418-1.079) |

*The multiple logistic regressions with/without adjustment of age, sex, stage, tumor size, location, invasive depth, vascular invasion, perineural invasion and serum blood sugar of CRC patients.

UICC: Union for International Cancer Control

HR: Hazards ratio

95% CI: 95% Confidence interval

AC (Ante cibum= means before eating) serum blood sugar before surgery
Figure 1: Colon cancer cell lines Caco2, SW480, and SW620 incubated in varying glucose conditions affects cell cycle, proliferation, and migration. A. Through the WST-1 assay, cell proliferation of Caco2 and SW620 increased significantly for 24 h incubation in a high glucose concentration. Compared to that of 5 mM of D-(+)-glucose administration, the proliferation rate of Caco2 in 10 mM and 15 mM of D-(+)-glucose administration increased significantly ($P = 0.0053$ and $P < 0.0001$, respectively). The proliferation rate of SW620 by 10 mM and 15 mM of D-(+)-glucose administration increased significantly at 24 h ($P = 0.0035$ and $P < 0.0001$, respectively). B. For Caco2 and SW620 cells, the accumulation in the G1 phase decreased significantly after 24 h of incubation in varying glucose conditions, while the accumulation in the G2 phase increased significantly only under the high glucose conditions. Compared to the 5 mM D-(+)-glucose concentration, the accumulation of Caco2 cells in the G1 phase in the 10 mM and 15 mM D-(+)-glucose concentrations was decreased significantly at 24 h ($P = 0.0002$ and 0.0014, respectively), while the accumulation in the G2 phase was increased significantly in those higher concentrations ($P = 0.0186$ and 0.0152, respectively). For SW620 cells, the accumulation in the G1 phase was 51.15% in the 5 mM D-(+)-glucose concentration and 50.02% in the 10 mM of D-(+)-glucose concentration ($P = 0.0315$ and 0.089, respectively) vs. 47.93% in the 15 mM of D-(+)-glucose concentration, while the accumulation in the G2 phase was 6.53% in the 5 mM concentration ($P = 0.223$ and 0.032, respectively) vs. 8.20% in the 10 mM concentration and 5.54% in the 15 mM concentration. C. The cell migration ability of Caco2 cells was increased in the high glucose concentrations as indicated by narrower gaps at 48 h. After 24 h of incubation, the narrowest gap distances decreased at the higher glucose concentrations (but not reach significantly different, both $P > 0.05$). After 48 h, the gap distances narrowed down significantly at the higher concentrations (0.48 mm in 5 mM of D-(+)-glucose vs. 0.08 mm in 10 mM of D-(+)-glucose and 0 mm in 15 mM of D-(+)-glucose; $P = 0.017$ and 0.002, respectively).
Figure 2: The expressions of miR-16 are downregulated in high glucose conditions in vivo and in vitro and the expression of miR-16 related mRNAs. A. Reverse transcription-qPCR analysis of serum miR-16 expression level by normalizing to C. elegans synthetic lin-4 miR expression. B. Quantitative analysis of miR-16 expression in three colon cancer cell lines after incubation in three separate D-(+)-glucose concentrations (5, 10, and 15 mM) for 24 h. The relative expression levels of miR-16 were normalized to U6b expression. C. The mRNA expression levels of Myc, as determined by qPCR, were significantly higher in 10 mM of D-(+)-glucose (152%, \( P < 0.0001 \), dark gray) and 15 mM of D-(+)-glucose (145%, \( P = 0.0005 \), black) compared to the one in 5 mM of D-(+)-glucose (100%, light gray) in Caco2. D. The mRNA expression levels of Myb, Raf-1, and VEGFR2, as determined by qPCR. Compared to the one in 5mM of D-(+)-glucose, mRNA levels of Myb were higher in 10mM of D-(+)-glucose (135%, \( P = 0.060 \)) and 15 mM of D-(+)-glucose (206%, \( P < 0.0001 \)). The expression levels of Raf-1 mRNA were not significantly different in 10 mM of D-(+)-glucose (107%, \( P = 0.621 \)) and 15 mM of D-(+)-glucose (112%, \( P = 0.357 \)). Compared to 5 mM of D-(+)-glucose, the mRNA levels of VEGFR2 were significantly higher in 10 mM of D-(+)-glucose (163%, \( P = 0.0002 \)) and 15 mM of D-(+)-glucose (140%, \( P = 0.0015 \)). E. The proposed mechanism affecting colon cancers by glucose administration through miR-16 regulation.
Cellular miR-16 expression levels under various glucose concentrations

The expression of cellular miR-16 was quantified by qPCR in the CRC samples (Caco2, SW480, and SW620) that were cultured in different glucose concentrations for 24 h incubation. The expressions of miR-16 decreased in three colon cancer cell lines in high-glucose conditions compared with the 5 mM of D-(+)-glucose condition (Figure 2B); the expressions of miR-16 for Caco2 cells decreased to 83.42% in 10 mM of D-(+)-glucose ($P = 0.420$) and to 60.27% in 15 mM of D-(+)-glucose ($P = 0.027$); the expressions of miR-16 for SW480 cells decreased to 61.42% in 10 mM of D-(+)-glucose ($P = 0.066$) and to 47.75% in 15 mM of D-(+)-glucose ($P = 0.007$); the expressions of miR-16 for SW620 cells decreased to 87.74% in 10 mM of D-(+)-glucose ($P = 0.565$) and to 34.97% in 15 mM of D-(+)-glucose ($P < 0.0001$). These results imply that the invasive colon cancer cell line was affected more significantly by high blood sugar than was the less invasive one.

The results of target genes prediction and mRNA quantitative assay

Our experiments showed that high glucose conditions can enhance cell proliferation in 3 colon cancer cell lines and decrease the population of arrested cells in the G0/G1 phase. We identified miR-16 target genes that may elucidate the proliferation and anti-oncogenic effects by bioinformatic analysis. Multifunctional, transcription factors, Myb and Raf1, which play a role in cell cycle progression and cellular transformation, and angiogenesis-related and cell-survival genes, VEGF and VEGFR2, were predicted.

After 24 h incubation in high glucose conditions, the mRNA levels of Myc for Caco2 cells increased significantly to 152% in 10 mM of D-(+)-glucose ($P = 0.0001$) and 145% in 15 mM of D-(+)-glucose ($P = 0.0005$), compared with the baseline condition (5 mM of D-(+)-glucose, Figure 2C). When cellular Myc mRNA were overexpressed under high glucose circumstances, the cellular miR-16 expression is suppressed, and subsequently miR-16 target genes, Myb and VEGFR2 mRNA were overexpressed (Figure 2D). Compared with 5 mM of D-(+)-glucose, the Myb mRNA levels increased to 135% in 10 mM glucose ($P = 0.060$) and 206% in 15 mM glucose ($P < 0.0001$), and the VEGFR2 mRNA levels increased significantly to 163% in 10 mM of D-(+)-glucose ($P = 0.0002$) and 140% in 15 mM of D-(+)-glucose ($P = 0.0015$). The high glucose concentrations slightly increased Raf-1 mRNA expression to 107% in 10 mM of D-(+)-glucose ($P = 0.621$) and 112% in 15 mM of D-(+)-glucose ($P = 0.357$).

Survival analysis

DFS and OS of the 520 UICC stage I to III CRC patients were assessed by the Kaplan-Meier method (Figure 3). Both DFS ($P < 0.0001$, Figure 3A) and OS ($P = 0.0017$, Figure 3B) were significantly poorer in the high blood glucose group ($\geq 110$ mg/dL) compared to those in the normal blood glucose group ($< 110$ mg/dL).

DISCUSSION

CRC is a disease with a complex etiology, and the mechanisms underlying this pathophysiology are not yet fully understood. Investigations of epigenetic modifications have accounted for the majority of research into complex diseases, and studies of this type have indicated that miRs could possibly serve as potential biomarkers of cancer [5, 7, 32]. The most fundamental metabolism alteration in CRC cells is the increase in glycolysis [10, 33]. Glucose may drive cancer not only by modifying miR expression levels but also by activating the mammalian target of rapamycin, which can increase protein synthesis and cellular growth [34–38]. In this study, we observed a higher incidence of postoperative recurrence in hyperglycemia patients and confirmed the vital role of miR-16 in hyperglycemic CRC patients. Through a series of in vitro studies, we showed that high glucose conditions can enhance cell proliferation in 3 colon cancer cell lines, decrease the population of arrested cells in the G0/G1 phase, as well as increase cell migration. Following glucose administration, miR-16 expression was inhibited through the overexpressed Myc gene, as in previous reports [39, 40]. Moreover, the expressions of Myb and VEGFR2 mRNA, which are target genes of miR-16, were shown to be upregulated.

This study offers biological plausibility for the hypothesis that hyperglycemia decreases serum miR-16 expression in CRC patients. Specifically, the experimental results showed that subjecting the Caco2, SW480, and SW620 colon cancer cells to high concentrations of glucose can increase the proliferation of the cells and decrease their accumulation in the G1 phase. miR-15a and miR-16-1 as the miR-15a/16-1 cluster are located on chromosome13q14 and the region was deleted in more than half of chronic lymphocytic leukemia cases and accelerated the proliferation of human B cells by modulating the expression of genes controlling cell-cycle progression [41]. Previous studies have shown that miR-16 partially induces cell-cycle arrest by regulating multiple cell-cycle genes, including cyclin D1, cyclin D3, cyclin E1, and CDK6, and by preventing cells from entering the S phase, causing an accumulation of cells in the G0/G1 phase [42]. The miR-16 family inhibits cellular growth and cell cycle progression, and triggers the G0/G1 accumulation phenotype in diverse cell lines, including HCT116, DLD-1, A549, MCF7, and Tov21G cells [43, 44].

Through a literature review, we have learned that multiple targets regulated by an individual miR can act in a coordinated manner to regulate the same biological process [43]. The vascular endothelial growth factor (VEGF) plays an important role in tumor development, growth, and metastasis [45]. Dejean et al. have shown that
downregulation of miR-16 induces VEGF expression, tumor angiogenesis, and growth in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas [46]. Vascular endothelial growth factor receptor (VEGFR) can be expressed on the cell surface of several tumor types [47], and we have shown that a high glucose level can enhance VEGFR2 mRNA expression by suppressing miR-16 expression. Overexpressed VEGF not only stimulates angiogenesis for tumor growth but also acts with VEGFR on the tumor-cell surface as an autocrine growth factor to enhance the tumor [47]. We propose that downregulated miR-16 results in upregulating two VEGF pathway proteins, VEGF and VRGFR2, simultaneously and enhances tumor growth by both VEGF autocrine and angiogenesis. c-Myb portion, a transcription factor, is highly expressed in the gastrointestinal tract [48]. Overexpression of c-Myb increases the tumorigenesis of colon-cancer cells and poor prognosis for CRC patients [49, 50]. In high glucose conditions, miR-16 expression were suppressing and resulted in overexpressing of miR-16 target genes c-Myb and VEGFR2 and led to colon cancer cell proliferation and migration.

Figure 3: Cumulative survival rates of the 520 UICC stages I to III patients with colorectal cancer (CRC) as assessed by the Kaplan-Meier method, and differences in survival rates analyzed by the log-rank test. A. Disease-free survival in CRC patients was significantly lower in the high serum glucose group (≧110 mg/dL, gray line) than in the low serum glucose group (<110 mg/dL, black line) (P < 0.0001). B. Overall survival in CRC patients was significantly lower in the high serum glucose group (≧110 mg/dL, gray line) than in the low serum glucose group (<110 mg/dL, black line) (P = 0.0017).
The meta-analysis showed a positive correlation of diabetes mellitus and increased risk of CRC [11]. The present data shows that stage I-III CRC patients with high blood sugar levels have a larger tumor size, more perineural invasion, and markedly poor prognosis, including a poor DFS and OS. We further stratified the CRC patients according to their DM status and found that those patients either with or without DM history but whose blood sugar levels were below 110mg/dL had a lower incidence of relapse. Previous studies indicate that miRs in the plasma microvesicles might regulate the progression of cell-cycle proteins [51, 52]. Since CRC patients with hyperglycemia are observed to express lower serum miR-16 levels, and they are more prone to having poor clinical outcomes, miR-16 has an antitumorigenesis effect on colon cancer cells. This study suggests that circulating miR-16 can serve as a novel and convenient biomarker for post-operative surveillance, so regular serum miR-16 expression tests are recommended. However, further large-scale follow-up studies are needed to demonstrate this hypothesis.

In this study, we only included the fasting blood sugar levels, which reflect daily blood glucose level, but which also might be prone to bias. HbA1C levels can be tested at any time, notwithstanding the duration of fasting or the type of prior meal, and HbA1c levels reflect blood glucose levels over the past 6 to 8 weeks [53]. The HbA1c levels may thus be more crucial in terms of their prognostic impact for CRC patients, but we did not have Hba1c data for every patient in the current study. At present, however, we are conducting another study that combines fasting plasma glucose and HbA1C data to determine if HbA1C is more crucial in terms of its prognostic impact for CRC patients.

In summary, data from this study show that miR-16 has anti-oncogenic effects, including the inhibition of colon-cancer cell proliferation and migration. The association between hyperglycemia, decreased levels of miR-16, and prognosis in CRC patients suggest that blood sugar levels and serum miR-16 of patients are potential surrogate biomarkers for identifying high-risk stage I-III CRC patients after radical resection.

MATERIALS AND METHODS

Patients and tumor samples

In this retrospective study, CRC patients for whom fasting blood glucose levels were not determined, those with incomplete medical records, and those with stage IV disease or without the informed consent were excluded. Demographic data were obtained for 520 patients with primary CRC at the American Joint Commission on Cancer/International Union Against Cancer (AJCC/ UICC) [1] stages I to III between January 2005 and July 2011; each of the patients enrolled in the study signed an informed consent indicating their agreement to participate. Impaired carbohydrate metabolism was defined as one of the ADA 2003 diagnostic criteria (diabetes: fasting plasma glucose [FPG]: ≥126 mg/dL; impaired fasting glucose [IFG]: 110-125 mg/dL; normal: <110 mg/dL) [26, 27]. The blood sugar levels of all 520 CRC patients were determined using blood samples collected when the patients had achieved fasting status, and of these 520 patients, 312 had fasting glucose levels between 70 and 109 mg/dL (less than 110 mg/dL: normal glucose group) and 208 patients had levels between 110 and 395 mg/dL (no less than 110 mg/dL: high glucose group). Furthermore, serum miR-16 levels were measured in 90 patients (46 samples from the normal glucose group and 44 samples from high glucose group). The diagnoses of diabetes mellitus (DM) were based on the DM chart history or by taking anti-hyperglycemic agents for DM. All subjects were unrelated ethnic-Chinese residents in Taiwan. Each patient provided written informed consent for collecting their clinical samples and to publish their case details, and all patient data were anonymized. The study protocol was approved by the Kaohsiung Medical University Hospital Institutional Review Board (Protocol Number: KMUHIRB-2012-04-02(I)). All patients received follow ups until either their death or December 2012. The median follow-up time was 37 months (range: 3 to 95 months). Disease-free survival (DFS) was defined as the time between primary surgery and the recurrence of colon cancer or the last follow-up appointment. Overall survival (OS) was defined as the elapsed time between primary surgery and death from any cause or the last follow-up appointment.

Cell culture

The Caco2 and SW480 colon cancer cell lines were established from primary adenocarcinoma of the colon, and the SW620 cell line was established from a lymph node metastasis of the same patient. The human colon carcinoma cell lines Caco2, SW480, and SW620 (ATCC, Manassas, VA, USA) were cultured in low glucose DMEM (5 mM D-(+)-glucose, Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS; Gibco-BRL) and 100 U/mL of penicillin, as described previously [28]. The cells were maintained at 37°C in an atmosphere of 5% CO₂.

Analysis of cell proliferation

CRC cell lines Caco2, SW480, and SW620 were seeded in 96-well plates in the baseline glucose DMEM (D-(+)-glucose 5 mM, Gibco-BRL) as described above. Cells were treated (4 wells per treatment) in various D-(+)-glucose concentrations (5, 10, or 15 mM) for 22 h. To determine cell proliferation, cells were further incubated with 1/10 volume of WST-1 reagent (Roche Diagnostics
DNA contamination. DNase treatment (Qiagen) was executed to remove any temperature and dissolved in 30 μL of distilled water. The RNA pellet was dried for 10 min at room ethanol. The RNA pellet was washed twice by centrifugation with 70% chloroform extraction and precipitation with isopropanol, mixed solution was centrifuged. After an additional μL of chloroform were added to the sample, and the Cel-lin-4 (Invitrogen), with minor modifications: 6 μL of 1 nM lin-4 (C. elegans) miRs as normalization controls, stably expressed endogenous circulating miRNAs, were chosen and treated with different glucose concentrations (5, 10, or 15 mM) for 48 h.

Wound healing assay

Colon cancer cell lines, Caco2, SW480, and SW620 were seeded in 6-well plates as described above. Caco2 and SW620 cells were incubated (3 wells per treatment) for 24 h with various D-(+)-glucose concentrations (5, 10, or 15 mM) and cell cycles were quantified using propidium iodide (PI, Sigma-Aldrich Co, MO, USA) staining and subsequently analyzed using a FACSScan cytometer (Becton Dickinson, NJ, USA) with CellQuest software (BD Biosciences), according to the manufacturer’s instructions. Since SW480 cells were slower to grow than the other cell lines in the proliferation assay, SW480 cells were chosen and treated with different glucose concentrations (5, 10, or 15 mM) for 48 h.

Serum preparation and RNA extraction

The venous blood was obtained prior to the operation. The blood samples were centrifuged at 3000 rpm for 15 min, and the serum was aliquoted into 1.7-mL eppendorf tubes. In the absence of well-documented, stably expressed endogenous circulating miRs as normalization controls, C. elegans synthetic lin-4 miR (Cel-lin-4, Part Number: 4398988, Invitrogen, Carlsbad, CA, USA), which had been added to the serum preparation prior to RNA extraction, was used as a normalization control, following the procedure described in earlier studies [29, 30]. For the isolation of RNA from the serum, 300 μL of serum were homogenized in 900 μL of TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. Total RNA, including mRNA and miR, was purified with Qiagen RNAeasy Columns (Qiagen, Hamburg, Germany). For measuring the miR-16 expression level of CRC cells, miR-16 cDNA was synthesized and TaqMan miR RT-qPCR assay was used, as previously described. The relative expression levels of miR-16 were normalized to that of U6b using the equation log₂ΔCt = (Ct_U6b − Ct_Cel-lin-4). The mean and standard deviation (SD) values of log₂ΔCt were calculated.

Colon cancer cellular miR-16 expression levels

Approximately 10⁷ cells were lysed in 1 mL of TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. Total RNA, including mRNA and miR, was purified with Qiagen RNAeasy Columns (Qiagen, Hamburg, Germany). For measuring the miR-16 expression level of CRC cells, miR-16 cDNA was synthesized and TaqMan miR RT-qPCR assay was used, as previously described. The relative expression levels of miR-16 were normalized to that of U6b using the equation: log₂ΔCt = (Ct_U6b − Ct_miR-16). The mean and standard deviation (SD) values of log₂ΔCt were calculated.

Target genes prediction

To investigate the biological functions of the miR-16, its target genes were searched by using several miR target prediction programs [31], which include TargetScanS (http://genes.mit.edu/targetscan), miRDB (http://mirdb.org/miRDB), miRanda (http://www.microrna.org/microrna/home.do), and miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/). Pathway analyses of miR-16 target genes were conducted using the KEGG pathway program (http://www.genome.jp/kegg/kegg2.html).

mRNA quantitative assay

For the mRNA quantitative assay, cDNAs were synthesized from 1 μg of total RNA with random hexamers primers using Reverse Transcriptase (Applied Biosystems Inc.), and RT real-time PCR with SYBR Green (Applied Biosystems Inc.) was performed with the paired primers listed in Supplementary Table S1.

Statistical analysis

All data were statistically analyzed using JMP software version 10.0 (SAS Institute Inc., Cary, NC, USA). The continuous variables are represented as mean ± standard deviation (SD) values, and the dichotomous variables are represented as number and percentage values.
A T-test was used to analyze continuous variables. A Chi-square test was used where applicable for the univariate statistical analysis, and a Cox regression hazard model was used for multivariate analyses of OS and DFS. The survival plot was calculated by the Kaplan-Meier method, and the differences in survival rates were analyzed by the log-rank test. An analysis of covariance was performed to compare the mean levels of miR expression between subjects with different blood sugar levels. A two-tailed P value of less than 0.05 was considered statistically significant.

ACKNOWLEDGMENTS

This work was supported by grants from the Excellence for Cancer Research Center Grant through funding by the Ministry of Science and Technology (MOST103-2325-B-037-005) and the Ministry of Health and Welfare (MOHW105-TDU-B-212-134005), Taiwan, Republic of China, as well as grants from Kaohsiung Medical University Hospital (KMUH103-3R16, KMUHS10304, KMUHS10305), the Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University (KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

CONFLICTS OF INTEREST

The authors have no potential conflicts of interest to disclose.

REFERENCES

1. Edge SB and Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–1474.
2. Becker H. [Surgery of colorectal carcinoma]. Praxis (Bern 1994). 1995; 84:1371–1372.
3. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hase K, Oya M, Maeda K, Hirai T, Kameyama M, Shirozuka K and Muto T. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007; 141:67–75.
4. Vickers AJ, Bianco FJ, Jr., Boorjian S, Scardino PT and Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer. 2006; 106:576–580.
5. Wang Y, Jatko T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL and Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004; 22:1564–1571.
6. Yeh YS, Wang HM, Lin SR and Wang JY. Prognostic and Molecular Factors in Stage II Colorectal Cancer. Genomic Med Bio Mark Health Sci. 2011; 3:2–8.
7. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010; 42:1273–1281.
8. Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY and Juo SH. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis. 2012; 33:1522–1530.
9. Biswas S, Lunec J and Bartlett K. Non-glucose metabolism in cancer cells-is it all in the fat? Cancer Metastasis Rev. 2012.
10. Flavin R, Zdra G and Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011; 223:283–294.
11. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. World J Gastroenterol. 2015; 21:6026–6031.
12. Rottiers V and Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012; 13:239–250.
13. Fernandez-Hernando C and Moore KJ. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol. 2011; 31:2378–2382.
14. Cho WC. Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev Mol Diagn. 2011; 11:691–694.
15. Slaby O, Svoboda M, Michalek J and Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009; 8:102.
16. Schetter AJ and Harris CC. Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol. 2011; 38:734–742.
17. Cho W. MicroRNAs in cancer translational research. Berlin, Germany: Springer. ed.
18. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J and Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett. 2007; 113:76–82.
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsens BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513–10518.
20. Matsumura T, Sugimachi K, Inuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, Shiinden Y, Eguchi H, Yamamoto H, Doki Y, Mori M, Ochiya T, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015; 113:275–281.
21. Li J, Liu Y, Wang C, Deng T, Liang H, Wang Y, Huang D, Fan Q, Wang X, Ning T, Liu R, Zhang CY, Zen K, Chen X and Ba Y. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Sci Rep. 2015; 5:12921.

22. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T and Tsuchiya N. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014; 9:e92929.

23. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF and Jeyaseelan K. Circulating miRNA Profiles in Patients with Metabolic Syndrome. J Clin Endocrinol Metab. 2012; 97:E2271–E2276.

24. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J and Mayr M. Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes. Circ Res. 2010; 107:810–817.

25. Wang X, Wang J, Ma H, Zhang J and Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012; 29:919–927.

26. Mollar-Puchades MA, Pallares-Carratala V, Navas de Solis MS and Pinon-Selles F. [Fasting glucose versus oral glucose tolerance testing in the diagnosis of diabetes mellitus]. Rev Esp Cardio. 2006; 59:1349–1350.

27. Genuith S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Kröger WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26:391–398; discussion 399.

28. Wu TJ, Yeh CN, Chao TC, Jan YY and Chen MF. Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg. 2006; 30:391–398; discussion 399.

29. Hoegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED and Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012; 130:1378–1386.

30. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283:33394–3405.

31. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ and Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer. 2010; 10:173.

32. Albulescu R, Neagu M, Albulescu L and Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev Mol Diagn. 2011; 11:101–120.

33. Liu X, Lazenby AJ and Siegal GP. Signal transduction cross-talk during colorectal tumorigenesis. Adv Anat Pathol. 2006; 13:270–274.

34. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008; 7:1520–1524.

35. Leontieva OV, Demidenko ZN and Blagosklonny MV. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis. 2014; 5:e1214.

36. Leontieva OV, Paszkiewicz G, Demidenko ZN and Blagosklonny MV. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis. 2013; 4:e472.

37. Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis. 2013; 4:e964.

38. Leontieva OV, Paszkiewicz GM and Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell. 2014; 13:616–622.

39. Elouil H, Cardozo AK, Eizirik DL, Henqujn JC and Jonas JC. High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NFkappaB. Diabetologia. 2005; 48:496–505.

40. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E and Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012; 31:3002–3008.

41. Klein U, Mia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G and Dalla-Favera R. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010; 17:28–40.

42. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z and Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008; 36:5391–5404.

43. Carleton M, Cleary MA and Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle. 2007; 6:2127–2132.

44. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, Jackson AL, Carleton M and Lim L. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007; 27:2240–2252.

45. Guan H, Zhou Z, Wang H, Jia SF, Liu W and Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin Cancer Res. 2005; 11:2662–2669.
46. Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prosper F, Felsher DW, Cavaille J, Prats H, Delsol G, Giuriato S, et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia. 2011; 25:1882–1890.

47. Tian X, Song S, Wu J, Meng L, Dong Z and Shou C. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun. 2001; 286:505–512.

48. Ess KC, Witte DP, Bascomb CP and Aronow BJ. Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation. Oncogene. 1999; 18:1103–1111.

49. Naik P, Karrim J and Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 1996; 10:2105–2116.

50. Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B and Zupi G. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001; 158:1289–1299.

51. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann R, Jr., Srikantan S, Subrahmanyan R, Martindale JL, Yang X, Ahmed F, Navarro F, Dykxhoorn D, Lieberman J and Gorspe M. p16(INK4a) translation suppressed by miR-24. PLoS One. 2008; 3:e1864.

52. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14:791–798.

53. Okosun IS, Seale JP, Lyn R and Davis-Smith YM. Improving Detection of Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests. Front Public Health. 2015; 3:260.